NEW YORK, NY–(October 21, 2014) – In the recently released preliminary results from Plandaí Biotechnology’s (OTCQB: PLPL) human clinical trial that compared its green tea extract to a commercially available extract, Professor Anne Grobler and her team at North West University in South Africa proved that all 8 catechins found in the green tea plant were absorbed into the bloodstream of those using Phytofare^™ Catechin Complex, including, the most potent catechin of the eight, epigallocatechin-3-gallate or EGCG.

Plandaí’s unique and proprietary process known as “hydrodynamic sheering” which unzips the molecules of the “live” green tea plant, releases all of the phytonutrients, and then rearranges the molecules into a biocompatible format. As the preliminary clinical trial results show, that process is producing a more bioavailable extract. In what has been a difficult and lengthy fight against Alzheimer’s disease, what difference could a more potent extract make while battling the 6th leading cause of death in America?

Alzheimer’s disease is a progressive, devastating, and eventually fatal neurodegenerative brain disorder that is believed to occur when a type of plaque (amyloid plaque) builds up in the brain and deprives brain cells of oxygen. This lack of oxygen will kill the brain cells and eventually lead to memory and speech loss, diminished motor skills and then death.

In his article, How Green Tea Protects Against Alzheimer’s Disease, for the August 2014 edition of Life Extension Magazine, Michael Downey explains that recent developments have uncovered one of green tea’s most exciting benefits discovered to date: its potential to prevent-and possibly reverse-the effects of Alzheimer’s disease and other forms of dementia.

Downey writes that “researchers found that the potent green tea compound EGCG gets to the root of Alzheimer’s disease by three distinct mechanisms: preventing the buildup of amyloid plaques, breaking down existing plaques, and triggering production of new neurons in the brain. As a result, green tea consumption has now been associated with a 54% reduction in the risk of developing cognitive decline.”

A number of studies have been performed using an extract made of a heightened dose of the potent EGCG catechin, a dose much like Plandaí Biotechnology might be able to produce using its “live” plant processing technology.

First, Jeffrey B. Blumberg, a director of Tufts University’s HNRCA Antioxidants Research Laboratory, found that “recent studies on flavonoids, phytochemicals especially rich in plant foods like berries and tea, show they may act to promote brain performance and/or reduce the risk for neurodegenerative conditions.”

Meanwhile, researchers in Switzerland, who were published in the European Journal of Clinical Nutrition, concluded that green tea beverages were associated with increased activity in the dorsolateral prefrontal cortex of the brain. This is a key area for working memory processing. The researchers found the activity was greater still with the higher dose of the green tea extract.

Downey’s research agrees as he writes, “laboratory investigations have revealed that-unlike other flavonoids-green tea compounds are able to reduce neurodegeneration.”

A further study used mice to test the brain cell effects of EGCG. Chinese researchers, published their findings in Molecular Nutrition & Food Research and found that treatment with EGCG significantly increased the number of cells associated with neurogenesis. When mice were injected with EGCG, their performance in navigating a maze markedly improved-a sign of increased spatial cognition.

So, the question Plandaí’s future research could address is; can its Phytofare^™ Catechin Complex produced from the company’s proprietary technology duplicate that same green tea extract by highlighting the EGCG catechin used in many of the aforementioned studies, and then, through its use, potentially block the formation of the amyloid plaques in the brain that lead to Alzheimers disease.

About Stock Market Media Group
SMMG is a Research and Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, CEO interviews and feature news articles. SMMG is compensated $3,500 per month by Plandai Biotechnology for content development. Previously, SMMG was compensated for similar content by a third party which occurred from April 2013 through June 2014. During that period, SMMG received approximately $55,000 for its content. Neither SMMG nor anyone associated with it owns shares in PLPL. For more information: www.stockmarketmediagroup.com.

Contact:
Stock Market Media Group
info@stockmarketmediagroup.com